Price Alert: Shares of Y-Mabs (YMAB) Trade 9.83% Higher at Midday June 21

Equities Staff  |

Shares of Y-Mabs Therapeutics Inc (NASDAQ: YMAB) rose 9.83% Tuesday.

As of 12:12:58 est, Y-Mabs sits at $12.66 and has moved $1.13 so far today.

Y-Mabs has moved 14.77% over the last 30 days and has a YTD change of 29.06% based on the previous close.

The company is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Y-Mabs visit the company profile.

About Y-Mabs Therapeutics Inc

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.

To get more information on Y-Mabs Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Y-Mabs Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content